Tag: NASDAQ ADXS

Business

Advaxis, Inc. (NASDAQ: ADXS) Initiation of Phase 1 Clinical Trial of ADXS-504 for the Early Prostate Cancer Treatment

Advaxis, Inc. (NASDAQ: ADXS) a biotechnology company in the clinical stage concentrated on developing immunotherapy products, announced the initiation of its Phase 1 clinical study of ADXS-504 in patients with recurrent prostate cancer on July 15, 2021. The clinical study being executed at Irving Medical Center, Columbia University, is the […]

Business

Arbutus Biopharma Corp (NASDAQ: ABUS) Receives A Nod To Investigate New Drug, Rosen Law Firm Issues Loss Alert, Halper Sadeh LLP Initiates Investigating Companies

Arbutus Biopharma Corp (NASDAQ: ABUS) is back in the news. First, the company announced that it had received a go-ahead from the U.S. Food and Drug Administration to investigate New Drug (IND) application for AB-729 in a Phase 2a clinical trial. The Phase 2a proof-of-concept clinical trial will evaluate the […]

Business

Advaxis, Inc. (NASDAQ: ADXS) Will Be Biosight Therapeutics With A Cash Position Of $50 Million

Advaxis, Inc. (NASDAQ: ADXS) recently announced to have entered into a definitive merger agreement with Biosight Ltd., according to which the shareholders of Biosight will become the majority holders of the combined company upon completion of the transaction. With approximately $50 million in cash, cash equivalents, and marketable securities, the […]